These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 540479

  • 1. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
    Colombo L, Monarca A, Goldberg D, Zanetta R.
    Clin Ter; 1979 Oct 31; 91(2):155-71. PubMed ID: 540479
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Bis-(hydroxy-2-ethylthyo)-1,10-decano in hyperlipaemic therapy (author's transl)].
    Cucinotta D, Palummeri E, Ceccato S, Passeri M.
    G Ital Cardiol; 1977 Oct 31; 7(3):248-64. PubMed ID: 858465
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K, Krempler F, Schellenberg B, Schlierf G.
    Acta Med Austriaca; 1979 Oct 31; 6(3):90-4. PubMed ID: 547652
    [Abstract] [Full Text] [Related]

  • 6. [Clinical study of thiadenol in diabetic hyperdyslipemia as compared with clofibrate].
    Nicrosini F, Pasotti C.
    Clin Ter; 1979 Aug 15; 90(3):241-50. PubMed ID: 553752
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [The clinical use of bis-(hydroxy-ethyl-thio)-1,10-decane in the treatment of hyperlipemic and dyslipemic conditions].
    Vailati G, Montini M, Simonutti M, Nosari I, Pagani G.
    Clin Ter; 1978 May 31; 85(4):361-73. PubMed ID: 668273
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Indications and limitations of tiadenol therapy of dyslipidemia in the elderly].
    Passeri M, Cocchi C, Ceccato S, Palummeri E, Cucinotta D.
    G Clin Med; 1979 Jan 31; 60(1):49-64. PubMed ID: 456778
    [No Abstract] [Full Text] [Related]

  • 13. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV.
    Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409
    [No Abstract] [Full Text] [Related]

  • 14. [Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
    Rajecová E, Klimes I, Seböková E, Rychnavská E, Pleváková L, Linke-Cvrkalová A, Langrová H.
    Vnitr Lek; 1995 Oct 15; 41(10):677-81. PubMed ID: 8578698
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gemfibrozil and clofibrate in the treatment of hyperlipidaemias. A comparative trial.
    Eisalo A, Manninen V.
    Proc R Soc Med; 1976 Oct 15; 69 Suppl 2(Suppl 2):44-6. PubMed ID: 798196
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Undesirable effects of hypolipemic drugs].
    Schettler G.
    Clin Ter; 1980 Mar 15; 92(5):457-67. PubMed ID: 7449323
    [No Abstract] [Full Text] [Related]

  • 20. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M, Montanari G, Gianfranceschi G, Malacrida MG, Battistin P, Morazzoni G, Tremoli E, Colli S, Maderna P, Sirtori CR.
    Atherosclerosis; 1983 Nov 15; 49(2):149-61. PubMed ID: 6365105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.